Released Mar 27, 2025, before the open
10-K filed Mar 27, 2025, 86 days after period end · 0002023658-25-000012
Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$20.96M-$20.96M derivedN/M vs Q4 2023N/M vs Q3 2024
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$26,637,000—
Operating Cash Flowderived-$30,032,000N/M
Free Cash Flowderived-$30,072,000N/M
What the release said
The release
Same quarter
| Metric | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures |
|---|---|---|
| Net Income | -$20.96M | -$12.44M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bicara Therapeutics Inc. · CIK 2023658 · Engraved from SEC EDGAR